The Biden Administration is launching a new National Biotechnology & Biomanufacturing Initiative designed to encourage investment in biotechnology via an executive order signed by the President on 12 September.
President Bio-den? Executive Order Highlights Value Of Biotech – But Doesn’t Change Pricing Message
The White House is playing up a new initiative to support ‘biotechnology and biomanufacturing.’ The focus on innovation is always a welcome theme – but it does not signal any change in the emphasis on cutting drug pricing in the Biden Administration.
More from Manufacturing
• By
Mechanisms in the draft treaty that the more than 190 member states of the World Health Organization have finally agreed to are expected to “materially affect companies,” particularly those that develop, manufacture or distribute pandemic-related health care products.
• By
The International Council for Harmonisation has consolidated and modernized its existing stability guidelines into one document, and addressed modern stability testing approaches like modeling, bracketing, and matrixing.
• By
Cellares’ fully automated cell therapy manufacturing platform is the first system to receive an Advanced Manufacturing Technology designation from US FDA
• By
The rollout of Trump’s plan has been a policy whiplash, but despite a 90-day pause on tariffs, the US president still appears to be holding a grudge with industry over drug pricing.